13 January 2021 - Patients aged 70 or younger with previously untreated CLL lived longer without disease progression compared to patients treated with FCR, a chemoimmunotherapy regimen.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved Imbruvica (ibrutinib) in combination with rituximab for the treatment of patients with previously untreated chronic lymphocytic leukaemia.

This latest approval is based on the Phase 3 ECOG1912 study (also referred to as E1912) that demonstrated newly diagnosed patients age 70 or younger (median age of 58) treated with Imbruvica plus rituximab had significantly improved progression-free survival compared to patients treated with fludarabine, cyclophosphamide and rituximab.

Read Janssen press release